本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

LAVA Therapeutics N.V.

1.41
+0.01991.43%
成交量:4.40万
成交额:6.15万
市值:3,708.78万
市盈率:-1.51
高:1.41
开:1.39
低:1.39
收:1.39
数据加载中...
2025/03/28

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/03/28

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/03/28

重要事件披露

Form 8-K - Current report
2025/02/28

重要事件披露

Form 8-K - Current report
2025/02/25

重要事件披露

Form 8-K - Current report
2025/01/02

重要事件披露

Form 8-K - Current report
2024/03/20

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/03/07

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/11/10

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/06/06

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/06/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/04/11

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/24

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/23

[修订]年度报告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/12/12

SEC问询函

CORRESP [Cover] - Correspondence
2022/10/03

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/09/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/04/20

SEC问询函

CORRESP [Cover] - Correspondence
2022/03/24

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]